Skip to main content

Dr. Ahmad Sajjadi comments on the donanemab decision

By March 12, 2024In the News

Ahmad Sajjadi, MD, PhD

Ahmad Sajjadi, MD, PhD, UCI Neurologist and UCI MIND faculty member, was quoted in Healthline regarding the recent announcement by FDA to delay the decision to approve Eli Lilly’s amyloid targeting drug, donanemab.  Click here to read the article.